Clinical Trial Detail

NCT ID NCT03387098
Title QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors NantKwest, Inc.
Indications

pancreatic adenocarcinoma

Therapies

GI-4000

Leucovorin

nab-paclitaxel

Bevacizumab

Avelumab

ALT-803

Fluorouracil

ETBX-011

Oxaliplatin

Aldoxorubicin

Capecitabine

Cyclophosphamide

Age Groups: adult senior

No variant requirements are available.